StockData
Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS) stock

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$315.34+16.79 (+5.62%)

Close on Nov 18, 2026Market cap $9.33BP/E 39.5Yield –

Krystal Biotech revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Krystal Biotech's revenue for the twelve months ending Jun 30, 2026 was $440.48M, up 22.6% year over year. For fiscal 2025 it was $389.13M, up 33.9% from the year before. The highest annual figure on record is $389.13M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$389.13M+33.9%
FY2024Dec 31, 2024$290.52M+473.0%
FY2023Dec 31, 2023$50.70M–
FY2022Dec 31, 2022$0–
FY2021Dec 31, 2021$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$119.22M+24.1%
Q1 FY2026Mar 31, 2026$116.36M+31.9%
Q4 FY2025Dec 31, 2025$107.11M+17.5%
Q3 FY2025Sep 30, 2025$97.80M+16.6%
Q2 FY2025Jun 30, 2025$96.04M+36.6%
Q1 FY2025Mar 31, 2025$88.18M+94.9%
Q4 FY2024Dec 31, 2024$91.14M+116.3%
Q3 FY2024Sep 30, 2024$83.84M+879.9%
Q2 FY2024Jun 30, 2024$70.28M–
Q1 FY2024Mar 31, 2024$45.25M–
Q4 FY2023Dec 31, 2023$42.14M–
Q3 FY2023Sep 30, 2023$8.56M–
Q2 FY2023Jun 30, 2023$0–
Q1 FY2023Mar 31, 2023$0–
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$0–

More Krystal Biotech figures

See a number that looks wrong?